[go: up one dir, main page]

MA31256B1 - Nouveaux anticorps humains anti-r7v et leurs utilisations - Google Patents

Nouveaux anticorps humains anti-r7v et leurs utilisations

Info

Publication number
MA31256B1
MA31256B1 MA32224A MA32224A MA31256B1 MA 31256 B1 MA31256 B1 MA 31256B1 MA 32224 A MA32224 A MA 32224A MA 32224 A MA32224 A MA 32224A MA 31256 B1 MA31256 B1 MA 31256B1
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies
new human
hiv
specifically
Prior art date
Application number
MA32224A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Original Assignee
Urrma R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39473318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31256(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urrma R & D filed Critical Urrma R & D
Publication of MA31256B1 publication Critical patent/MA31256B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/114—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)

Abstract

La présente invention porte sur de nouveaux anticorps humains capables de se lier de façon spécifique à l'épitope r7v du vih. Ces anticorps ont toutes les cdr humaines et sont capables de neutraliser de façon spécifique toutes les souches de hiv, comprenant les mutants d'échappement. Ces anticorps sont utiles pour le traitement d'une infection par le vih, en particulier dans des patients en échec de haart.
MA32224A 2007-03-22 2009-09-18 Nouveaux anticorps humains anti-r7v et leurs utilisations MA31256B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89635907P 2007-03-22 2007-03-22
PCT/EP2008/053317 WO2008113833A1 (fr) 2007-03-22 2008-03-19 Nouveaux anticorps humains anti-r7v et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31256B1 true MA31256B1 (fr) 2010-03-01

Family

ID=39473318

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32224A MA31256B1 (fr) 2007-03-22 2009-09-18 Nouveaux anticorps humains anti-r7v et leurs utilisations

Country Status (18)

Country Link
US (1) US20110123536A1 (fr)
EP (1) EP2137214A1 (fr)
JP (1) JP2010521189A (fr)
KR (1) KR20100014495A (fr)
CN (1) CN101679515A (fr)
AR (1) AR066396A1 (fr)
AU (1) AU2008228246A1 (fr)
BR (1) BRPI0808287A2 (fr)
CA (1) CA2681130A1 (fr)
CL (1) CL2008000820A1 (fr)
IL (1) IL201034A0 (fr)
MA (1) MA31256B1 (fr)
MX (1) MX2009009982A (fr)
RU (1) RU2009138922A (fr)
TN (1) TN2009000380A1 (fr)
TW (1) TW200846363A (fr)
WO (1) WO2008113833A1 (fr)
ZA (1) ZA200906516B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603520A4 (fr) 2010-08-10 2014-02-19 Ecole Polytech Agents thérapeutiques se liant aux érythrocytes
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
PL3575792T3 (pl) * 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
WO2014193804A1 (fr) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3107563B1 (fr) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Agents thérapeutiques de glycociblage
CN105020678B (zh) * 2015-08-04 2017-10-13 珠海金晟照明科技有限公司 透镜单元、透镜组件和路灯灯头
WO2017196819A2 (fr) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Anticorps anti-cytomégalovirus humain (hcmv) largement neutralisant et leurs procédé d'utilisation
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019191079A1 (fr) * 2018-03-26 2019-10-03 The University Of Chicago Procédés et compositions permettant de cibler une lectine de type c de cellules endothéliales sinusoïdales du foie et des ganglions lymphatiques (lsectine)
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
WO2021212021A2 (fr) * 2020-04-16 2021-10-21 Dana-Farber Cancer Institute, Inc. Anticorps anti-coronavirus et procédés d'utilisation associés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Also Published As

Publication number Publication date
CA2681130A1 (fr) 2008-09-25
CN101679515A (zh) 2010-03-24
IL201034A0 (en) 2010-05-17
CL2008000820A1 (es) 2008-08-22
ZA200906516B (en) 2010-05-26
WO2008113833A1 (fr) 2008-09-25
TN2009000380A1 (en) 2010-12-31
BRPI0808287A2 (pt) 2014-10-07
TW200846363A (en) 2008-12-01
MX2009009982A (es) 2010-03-04
KR20100014495A (ko) 2010-02-10
AU2008228246A1 (en) 2008-09-25
JP2010521189A (ja) 2010-06-24
AR066396A1 (es) 2009-08-19
US20110123536A1 (en) 2011-05-26
EP2137214A1 (fr) 2009-12-30
RU2009138922A (ru) 2011-04-27

Similar Documents

Publication Publication Date Title
MA31256B1 (fr) Nouveaux anticorps humains anti-r7v et leurs utilisations
Dixon The effect of obesity on health outcomes
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
MA30406B1 (fr) Nouveaux composes
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PH12013501242B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
MA33216B1 (fr) Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
FR2874825A1 (fr) Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
EA201190163A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К PcrV, ОБЛАДАЮЩЕЕ АКТИВНОСТЬЮ ПРОТИВ ПСЕВДОМОНАС
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин